Roles of EMA and National Authorities

Ian Rees
GMP Inspector, MHRA

27th October 2011
Presentation Outline

- Abbreviation glossary
- ATMPs – the regulatory setting
- EMA:
  - IWG
  - GMP Annex 2 revision
- NCA:
  - Advice and guidance
  - Inspections
  - Clinical Trial Authorisations
- Useful links
Abbreviation Glossary

- **ATMP** - Advanced Therapy Medicinal Product (GT, SCT, TEP)
- **CAT** - Committee for Advanced Therapy
- **EMA** - European Medicines Agency
- **GLP** - Good Laboratory Practice
- **GP** - Good Practice (Quality System under Blood & EUTCD)
- **GT** - Gene Therapy
- **IWG** - EMA’s GMP Inspectors Working Group
- **MA** - Marketing Authorisation
- **NCA** - National Competent Authority e.g. MHRA, PEI, Afssaps
- **SCT** - Somatic Cell Therapy
- **TEP** - Tissue Engineered Products
- **VHP** - Voluntary Harmonised Procedure
ATMPs - the regulatory setting

Transplants or Transfusions
Processing, preservation, storage, distribution

Borderline – classification of product: medicinal product?

Unlicensed (Hospital Exemption / Specials)

Pre-clinical
Safety

Clinical Trials
Phase I, II, III

Commercial

GP

EUTCD or Blood Directive
Donation, procurement & testing (processing)

GMP

GLP

Cert. of Quality & non-clinical data EMA

Clinical Trials national licence (CTA) NCA

Marketing Authorisation centralised licence (MA) (CAT) EMA

Advice and guidance EMA / NCA

Advice and guidance EMA / NCA

GMP MIA(IMP)

Dossier

Dossier

Dossier

GMP MIA

GMP
EMA - IWG

• Scope:
  - Maintain / update EU GMP
  - Harmonise inspections practices between NCAs
  - Maintain Mutual Recognition Agreements
  - Maintain the Community database (EudraGMP)
  - Interact with other bodies: FDA, PIC/S, WHO
• Participants: 44 NCA members, Commission
• Observers: EDQM, MRA partners, PIC/S, EU accession countries
• Others e.g. FDA, ICH, WHO
• Links to other EMA bodies: QWP, BWP, CHMP, CAT, industry
• Four 3-day meetings per year
EMA: Annex 2 revision overview

- Revision complete but not yet published
- Key guidance changes:
  - Scope – clarification of start points of GMP
  - Depth of guidance
  - Principle of Quality Risk Management (ICH Q9)
  - Interface with EUTCD / Blood Directive
  - Reference to GMP Annex 1
  - Dedicated facilities
  - Short shelf-life products
NCA – advice and guidance

• Early engagement!
• Areas:
  - Product classification, 44 requests since 2008
  - GMP: manufacturing facilities / Quality Systems
  - Manufacturing licence type(s) required
• Type of advice:
  - Regulatory / classification - free
  - Scientific - chargeable
NCA – Inspections

- All ATMP manufacture requires an appropriate manufacturer’s authorisation under medicinal product legislation
- All inspections are conducted by the local NCA
- In UK there are 4 types of authorisation:
  - For clinical trial products - MIA(IMP)
  - For products with a Marketing Authorisation - MIA
    - Currently only 1 ATMP with an MA
    - Inspection triggered by EMA
  - Unlicensed products (i.e. exempt from holding an MA):
    - Hospital Exemption – specific for ATMPs
    - Manufacturer’s Specials – available for all pharmaceuticals to supply special clinical need unmet by a licensed product
NCA – Hospital Exemption

- Purpose – to foster early stage product development
- For medicinal products in scope of ATMP regulation
- Prepared on non routine basis
- Prepared according to specific quality standards equivalent to ATMPs with centralised MA
- Scheme for manufacture authorised by the NCA
- Prepared and used in same Member State (no ‘export’)
- Used in a hospital
- Used under exclusive professional responsibility of a medical practitioner
- To comply with individual prescription for a custom made product for an individual patient
- Traceability, quality pharmacovigilance, standards equivalent to ATMPs with centralised MA
NCA – Clinical Trial Authorisation

• Required in each MS where a CT is to be conducted prior to trial commencement
• Always a national competence
• All ATMPs are covered by the CT Directive
• Timings for ATMPs and GMOs:
  - 30 days: initial assessment (extra 90 days if consult external committee)
  - 30 days: further information from applicant
  - 30 days assessment of further information
NCA – CTA: VHP

Key features:
- Heads of Medicines Agencies CTIFG initiative
- Single application, consolidated set of questions, approvable in a number of Member States
- Sponsor can decide not to submit nationally if a MS raises a specific condition not acceptable to the sponsor
- Currently no fees payable during the VHP phase
- Only core documents required, (e.g. Protocol, IB, IMP Dossier, manufacturer’s authorisations, labelling)
- Fixed timelines for Sponsor and Member States
- Addresses many criticisms of Clinical Trials Directive
NCA – CTA: VHP

• Launched March 2009, now at version 2
• 3 phases:
  - Request by sponsor
  - Assessment → letter of approvable CT
  - National CTA application, submit ≤21 days, approval ≤10 days
• Experiences:
  - 65 applications received of which there are 2 ATMPs
  - 1 negative outcome
  - 2 withdrawn
  - 1 not submitted nationally to any MS
Useful links

- EMA – What’s new in Inspections:

- Commission ‘Latest News on Pharmaceuticals’:

- GMP Volume 4:

- MHRA – advice form and how we regulate ATMPs:
  - http://www.mhra.gov.uk/Howweregulate/Advancedtherapymedicinalproducts/index.htm
Questions / Discussion

EU Pharma Regulation EXPLAINED